Found: 1
Select item for more details and to access through your institution.
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study.
- Published in:
- Oncologist, 2012, v. 17, n. 1, p. 15, doi. 10.1634/theoncologist.2011-0249
- By:
- Publication type:
- Article